Mucosis BV
This article was originally published in Start Up
Executive Summary
To date, the most common route of vaccination has been as an intramuscular injection, which raises a systemic immune response to the selected pathogen. Mucosal vaccines can trigger both a local and systemic immune response, limiting pathogen invasion at the point of entry. Mucosis BV is developing nasally and orally delivered mucosal vaccines to prevent and treat infectious and other diseases. Its technology is based on particles derived from inactivated Lactococcus lactis bacteria, which are used in cheese and buttermilk production and so are safe for human use.